Sarlósejtes vérszegénység: vizsgálatok itt: Uganda
6 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Where
- Kampala, Masaka, Tororo
- Életkor
- 12 év to 100 év
- People
- 354 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06439082 - 3. fázisNot yet taking people in UgandaA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Jinja, Kampala
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 1/2. fázisTaking peopleOptimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
- Where
- Kampala
- Életkor
- 11 év to 18 év
- People
- 250
- Run by
- Children's Hospital Medical Center, Cincinnati
See details and how to joinNCT07708714 - No phaseTaking peopleUganda Sickle Surveillance Study (US-3)
- Where
- Kampala
- Életkor
- Up to 12 hónap
- People
- 1 000 000
- Run by
- Children's Hospital Medical Center, Cincinnati
See details and how to joinNCT06301893 - No phaseTaking peopleEvaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening
- Where
- Jinja
- Életkor
- 18 év and over
- People
- 24 000
- Run by
- Makerere University
See details and how to joinNCT07610239 - No phaseNot yet taking people in UgandaDevelopment and Evaluation of an Information Management System and Communication System for Population-wide Point-of-care Infant Sickle Cell Disease Screening
- Where
- Kampala
- Életkor
- Up to 5 év
- People
- 24 000 worldwide
- Run by
- Makerere University
See details and how to joinNCT06563440